Invesco’s Acumen Pharmaceuticals ABOS Stock Holding History

Invesco’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-127,798	Closed	-$141K	–	3758
2025 Q1	$141K	Buy	127,798 +107,956	+544%	+$154K	﹤0.01%	3584
2024 Q4	$34.1K	Buy	19,842 +1,653	+9%	+$3.98K	﹤0.01%	3720
2024 Q3	$45.1K	Sell	18,189 -797	-4%	-$2.16K	﹤0.01%	3696
2024 Q2	$45.9K	Buy	+18,986	New	+$60.4K	﹤0.01%	3830

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Invesco's ABOS Position: Q2 2025 in Review

Invesco sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 127,798 shares — an estimated $141K sold.

Invesco first reported a position in ABOS in Q2 2024 and held it in 4 quarters. The position peaked at $141K in Q1 2025. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

Invesco reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Invesco sold 127,798 Acumen Pharmaceuticals shares in Q2 2025, an estimated $141K.
Invesco first reported a position in Acumen Pharmaceuticals in Q2 2024 and held it in 4 quarters.
Invesco's Acumen Pharmaceuticals position peaked at $141K in Q1 2025.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.